MECP2 targeting antisense oligonucleotides (Vico Therapeutics)

N/A

Report date: 2025/03/20 15:53:16
NME

Base Information

Drug NameMECP2 targeting antisense oligonucleotides (Vico Therapeutics)
Drug Alias NameRNA modulating therapy (Vico Therapeutics)antisense oligonucleotides (Vico Therapeutics)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionMethyl-CpG-binding protein 2 modulators
TargetsMethyl-CpG-binding protein 2
Therapy Area/IndicationsRett Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVico Therapeutics BV
China Registration ClassN/A

Develop Information

Active CompaniesVico Therapeutics BV
Inactive CompaniesN/A
Active IndicationsRett Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A